Radiotherapy & Oncology
Volume 95, Issue 2 , Pages 234-239 , May 2010

Retrospective analysis of definitive radiotherapy for patients with superficial esophageal carcinoma: Consideration of the optimal treatment method with a focus on late morbidity

Received 7 November 2008 ,Revised 25 December 2009 ,Accepted 23 January 2010.

References 

  1. Center for Cancer Control and Information Services, National Cancer Center, Japan.
  2. Registration Committee for Esophageal Cancer (ed.), Comprehensive registry of esophageal cancer in Japan, The Japan Society for Esophageal Diseases.
  3. Nishimura Y, Okuno Y, Ono K, Mitsumori M, Nagata Y, Hiraoka M. External beam radiation therapy with or without high-dose-rate intraluminal brachytherapy for patients with superficial esophageal carcinoma. Cancer. 1999;86:220–228
  4. Okawa T, Dokiya T, Nishio M, Hishikawa Y, Morita K. Multi-institutional randomized trial of external radiotherapy with and without intraluminal brachytherapy for esophageal cancer in Japan. Japanese Society of Therapeutic Radiology and Oncology (JASTRO) Study Group. Int J Radiat Oncol Biol Phys. 1999;45:623–628
  5. Yamada K, Murakami M, Okamoto Y, et al. Treatment results of chemoradiotherapy for clinical stage I (T1N0M0) esophageal carcinoma. Int J Radiat Oncol Biol Phys. 2006;64:1106–1111
  6. Nemoto K, Matsumoto Y, Yamakawa M, et al. Treatment of superficial esophageal cancer by external radiation therapy alone: results of a multi-institutional experience. Int J Radiat Oncol Biol Phys. 2000;46:921–925
  7. Nemoto K, Yamada S, Hareyama M, Nagakura H, Hirokawa Y. Radiation therapy for superficial esophageal cancer: a comparison of radiotherapy methods. Int J Radiat Oncol Biol Phys. 2001;50:639–644
  8. Kodaira T, Fuwa N, Kamata M, Furutani K, Tachibana H, Yamazaki T. Single-institute phase I/II trial of alternating chemoradiotherapy with 5-FU and nedaplatin for esophageal carcinoma. Anticancer Res. 2006;26:471–478
  9. Kodaira T, Fuwa N, Itoh Y, et al. Multivariate analysis of treatment outcome in patients with esophageal carcinoma treated with definitive radiotherapy. Am J Clin Oncol. 2003;26:392–397
  10. Yorozu A, Dokiya T, Oki Y. High-dose-rate brachytherapy boost following concurrent chemoradiotherapy for esophageal carcinoma. Int J Radiat Oncol Biol Phys. 1999;45:271–275
  11. Fuwa N, Nomoto Y, Shouji K, Kodaira T, Kamata M, Ito Y. Therapeutic effects of simultaneous intraluminal irradiation and intraluminal hyperthermia on oesophageal carcinoma. Br J Radiol. 2001;74:709–714
  12. Kaplan E, Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc. 1958;53:457–481
  13. Mantle N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163–170
  14. Cox D. Regression models and life table. J R Stat Soc. 1972;34:197–220
  15. Shinoda M, Hatooka S, Mori S, Mitsudomi T. Clinical aspects of multimodality therapy for resectable locoregional esophageal cancer. Ann Thorac Cardiovasc Surg. 2006;12:234–241
  16. Akagi Y, Hirokawa Y, Kagemoto M, et al. Optimum fractionation for high-dose-rate endoesophageal brachytherapy following external irradiation of early stage esophageal cancer. Int J Radiat Oncol Biol Phys. 1999;43:525–530
  17. Gaspar LE, Winter K, Kocha WI, Coia LR, Herskovic A, Graham M. A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report. Cancer. 2000;88:988–995
  18. Ishikura S, Nihei K, Ohtsu A, et al. Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol. 2003;21:2697–2702

PII: S0167-8140(10)00056-3

doi: 10.1016/j.radonc.2010.01.005

Radiotherapy & Oncology
Volume 95, Issue 2 , Pages 234-239 , May 2010

Article Tools

* Image Usage & Resolution